子宫内膜样癌免疫标志物表型与分级关系
研究对621例子宫内膜样子宫内膜癌肿瘤进行多平台分析,检测微卫星不稳定、肿瘤突变负荷、PD-L1表达及POLE突变等免疫标志物。结果显示高级别肿瘤中MSI-H、TMB-H及PD-L1表达均较低级别更常见,提示高级别肿瘤可能更具免疫原性、或更可能从免疫治疗中获益。
要点
- EEC中MSI-H总体占33%,G3为37%、G2为32%、G1为22%(p=0.007)。
- TMB-H总体占25%,G3为34%、G2为23%、G1为13%(p=0.006)。
- PD-L1表达总体占5.5%,G3为12%、G2为3.0%、G1为0.9%(p<0.0001)。
核心结论
- 高级别子宫内膜样癌似乎较低级别更具免疫原性,可能优先从免疫治疗中获益。
研究设计与样本
- 对621例肿瘤进行多平台分析,592个基因行二代测序;TMB-H定义为≥10个突变/兆碱基,NGS法MSI定义为≥46个位点,PD-L1阳性定义为IHC≥2+且>5%;采用卡方检验。
主要发现
- MSI-H总体见于33%的EEC,G3为37%、G2为32%、G1为22%(p=0.007)。
- TMB-H总体见于25%的EEC,G3为34%、G2为23%、G1为13%(p=0.006)。
- PD-L1表达总体见于5.5%的EEC,G3为12%、G2为3.0%、G1为0.9%(p<0.0001)。
- POLE突变见于4.5%(28/618),所有POLE突变肿瘤均为TMB-H,但MSI-H与PD-L1分别仅见于10.7%和14.8%的肿瘤。
- 三阴性(TN)表型(ER-/PR-/Her2-)在G1 EEC中为4%、G2为9%、G3为33%。
关键数值与推荐
- TMB-H阈值:≥10个突变/兆碱基;NGS法MSI-H阈值:≥46个位点;PD-L1阳性阈值:IHC≥2+且>5%。
临床怎么用
- 原文结论认为高级别肿瘤似乎更具免疫原性,可能优先从免疫治疗中获益;未给出具体临床用药方案。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Increasing grade of endometrioid endometrial cancer (EEC) is associated with aggressive behavior and poor prognosis. The traditional classification system is limited in its ability to guide treatment planning and prognostication. We identify distinct immune biomarker phenotypes using known markers of immunogenicity to identify patients who may benefit from immune therapy (IT). METHODS: 621 tumors were analyzed by multiplatform profiling. NextGen sequencing was performed on 592 genes. Tumor mutational burden (TMB) was defined as high (H) ≥10mutations/megabase. Microsatellite Instability (MSI) by NGS was ≥46 loci. PD-L1 positivity was ≥2+, >5% by IHC. Chi-square tests were used. RESULTS: Overall, MSI-H was found in 33% of EECs, most frequent in grade 3 (G3), followed by grade 2 (G2) and grade 1 (G1) tumors (G3: 37%, G2: 32%, G1: 22%, p = 0.007). TMB-H was identified in 25% of EECs. TMB-H was most common in G3, followed by G2 and G1 tumors (G3: 34%, G2: 23%, G1: 13%, p = 0.006). Overall, PD-L1 expression was found in 5.5% of EECs. G3 EECs had the most frequent PD-L1 expression, followed by G2 and G1 tumors (G3: 12%, G2: 3.0%, G1: 0.9%, p < 0.0001). We identified POLE mutations in 4.5% (28/618). All POLE mutated tumors harbored TMB-H phenotypes but MSI-H and PD-L1 were only present in 10.7% and 14.8% of tumors respectively, suggesting upregulation of T-cell immune response in only a fraction of POLE mutated EECs. Triple negative (TN) biomarker phenotype (ER-/PR-/Her2-) was evaluated as a potential surrogate marker of tumor immunogenicity. We identified TN phenotype in 4% of G1 EEC compared with 9% in G2 and 33% in G3, suggesting loss of hormone expression and possible greater immunogenicity with increasing tumor grade. CONCLUSIONS: High grade tumors appear to be more immunogenic than low grade tumors and may preferentially benefit from IT.
引用
- Jones NL, Xiu J, Rocconi RP, et al. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. Gynecol Oncol. 2019. PMID: 31882243. doi:10.1016/j.ygyno.2019.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。